Nicola de Prisco

Nicola de Prisco

Auto-generated profile, based on publicly available information

Nicola de Prisco

Department of Genetics and Development, Columbia University Irving Medical Center, New York, NY 10032, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2023 in Science Advances
Verified
Journal Article
Closed access
NPNicola de Prisco
Nicola de Prisco
CFCaitlin Ford
Caitlin Ford
NENathan D. Elrod
Nathan D. Elrod
WLWinston Lee
Winston Lee
LTLauren C. Tang
Lauren C. Tang
VGVincenzo A. Gennarino
Vincenzo A. Gennarino
Alternative polyadenylation (APA) creates distinct transcripts from the same gene by cleaving the pre-mRNA at poly(A) sites that can lie within the 3′ untranslated region (3′UTR), introns, or exons. Most studies focus on APA within the 3′UTR; however, here, we show that CPSF6 insufficiency alters protein levels and causes a developmental syndrome by deregulating APA throughout the transcript. In neonatal humans and zebrafish larvae, CPSF6 insufficiency shifts poly(A) site usage between the 3′UTR and internal sites in a pathway-specific manner. Genes associated with neuronal function undergo mostly intronic APA, reducing their expression, while genes associated with heart and skeletal function mostly undergo 3′UTR APA and are up-regulated. This suggests that, under healthy conditions, cells toggle between internal and 3′UTR APA to modulate protein expression.

21 December 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
SBSalvatore Botta
Salvatore Botta
NPNicola de Prisco
Nicola de Prisco
EMelena marrocco
elena marrocco
MRMario Renda
Mario Renda
MSMartina Sofia
Martina Sofia
Enrico Maria SuraceEnrico Maria Surace
Enrico Maria Surace
The genome-wide activity of transcription factors (TFs) on multiple regulatory elements precludes their use as gene-specific regulators. Here we show that ectopic expression of a TF in a cell-specific context can be used to silence the expression of a specific gene as a therapeutic approach to regulate gene expression in human disease. We selected the TF Krüppel-like factor 15 ( KLF15 ) based on its putative ability to recognize a specific DNA sequence motif present in the rhodopsin ( RHO ) promoter and its lack of expression in terminally differentiated rod photoreceptors (the RHO -expressing cells). Adeno-associated virus (AAV) vector–mediated ectopic expression of KLF15 in rod photoreceptors of pigs enables Rho silencing with limited genome-wide transcriptional perturbations. Suppression of a RHO mutant allele by KLF15 corrects the phenotype of a mouse model of retinitis pigmentosa with no observed toxicity. Cell-specific-context conditioning of TF activity may prove a novel mode for somatic gene–targeted manipulation.

2 February 2022 in STAR Protocols
Verified
Journal Article
Open access
WLWinston Lee
Winston Lee
NPNicola de Prisco
Nicola de Prisco
VGVincenzo A. Gennarino
Vincenzo A. Gennarino
Identifying a disease gene and determining its causality in patients can be challenging. Here, we present an approach to predicting the pathogenicity of deletions and missense variants for an autosomal dominant gene. We provide online resources for identifying patients and determining constraint metrics to isolate the causal gene among several candidates encompassed in a shared region of deletion. We also provide instructions for optimizing functional annotation programs that may be otherwise inaccessible to a nonexpert or novice in computational approaches.

15 March 2022 in STAR Protocols
Verified
Journal Article
Open access
NPNicola de Prisco
Nicola de Prisco
SBSalvatore Botta
Salvatore Botta
WLWinston Lee
Winston Lee
RSRezazadeh Sarallah
Rezazadeh Sarallah
ACAlexei Chemiakine
Alexei Chemiakine
VGVincenzo A. Gennarino
Vincenzo A. Gennarino
Quantifying differences in the amount of protein and mRNA caused by missense mutations in a gene of interest can be challenging, especially when using patient-derived primary cells, which are intrinsically variable. In this protocol, we describe how to culture patient-derived lymphoblast and fibroblast cell lines for later mRNA and protein quantification. We also describe the steps to examine variants of PUM1 in HEK293T cells, but the protocol can be applied to other proteins of interest.